Correlation Between SAB Biotherapeutics and Spero Therapeutics

Can any of the company-specific risk be diversified away by investing in both SAB Biotherapeutics and Spero Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SAB Biotherapeutics and Spero Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between SAB Biotherapeutics and Spero Therapeutics, you can compare the effects of market volatilities on SAB Biotherapeutics and Spero Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SAB Biotherapeutics with a short position of Spero Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of SAB Biotherapeutics and Spero Therapeutics.

Diversification Opportunities for SAB Biotherapeutics and Spero Therapeutics

-0.5

Correlation Coefficient

SAB Biotherapeutics  Spero Therapeutics

Very good diversification

The 3 months correlation between SAB and Spero is -0.5. Overlapping area represents the amount of risk that can be diversified away by holding SAB Biotherapeutics and Spero Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Spero Therapeutics and SAB Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SAB Biotherapeutics are associated (or correlated) with Spero Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Spero Therapeutics has no effect on the direction of SAB Biotherapeutics i.e., SAB Biotherapeutics and Spero Therapeutics go up and down completely randomly.

Pair Corralation between SAB Biotherapeutics and Spero Therapeutics

Assuming the 90 days horizon SAB Biotherapeutics is expected to generate 9.77 times more return on investment than Spero Therapeutics. However, SAB Biotherapeutics is 9.77 times more volatile than Spero Therapeutics. It trades about 0.01 of its potential returns per unit of risk. Spero Therapeutics is currently generating about -0.21 per unit of risk. If you would invest  7.20  in SAB Biotherapeutics on September 5, 2024 and sell it today you would lose (1.94) from holding SAB Biotherapeutics or give up 26.94% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	90.91%
Values	Daily Returns

SAB Biotherapeutics  vs.  Spero Therapeutics

SAB Biotherapeutics

Risk-Adjusted Performance

11 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in SAB Biotherapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly conflicting basic indicators, SAB Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Spero Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Spero Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest conflicting performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Pair Trading with SAB Biotherapeutics and Spero Therapeutics

The main advantage of trading using opposite SAB Biotherapeutics and Spero Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SAB Biotherapeutics position performs unexpectedly, Spero Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will offset losses from the drop in Spero Therapeutics' long position.

The idea behind SAB Biotherapeutics and Spero Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.